Edzard Schwedhelm Selected Research

Nisoldipine

10/2007	Telmisartan improves endothelial function in patients with essential hypertension.
4/2007	Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension.
3/2007	Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.
9/2006	Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edzard Schwedhelm Research Topics

Disease

39	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 12/2003
18	Hypertension (High Blood Pressure) 01/2022 - 01/2004
14	Atherosclerosis 01/2022 - 01/2004
12	Stroke (Strokes) 12/2021 - 03/2009
10	Heart Failure 01/2022 - 01/2004
9	Myocardial Infarction 01/2022 - 04/2008
9	Coronary Artery Disease (Coronary Atherosclerosis) 04/2021 - 07/2004
7	Atrial Fibrillation 01/2022 - 01/2016
7	Sepsis (Septicemia) 03/2021 - 10/2015
7	Diabetes Mellitus 06/2017 - 01/2004
6	Inflammation (Inflammations) 01/2022 - 07/2004
6	Ischemic Stroke 04/2021 - 10/2009
6	Hypercholesterolemia 02/2008 - 01/2004
5	Vascular Diseases (Vascular Disease) 01/2022 - 04/2008
5	Essential Hypertension 01/2020 - 09/2006
5	Chronic Renal Insufficiency 06/2017 - 05/2009
5	Insulin Resistance 09/2015 - 09/2006
5	Coronary Disease (Coronary Heart Disease) 03/2013 - 07/2006
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 11/2007
4	Parkinson Disease (Parkinson's Disease) 01/2021 - 10/2020
4	Fibrosis (Cirrhosis) 01/2020 - 11/2005
4	Type 2 Diabetes Mellitus (MODY) 01/2014 - 07/2005
3	Brain Ischemia (Cerebral Ischemia) 12/2021 - 09/2009
3	Neoplasms (Cancer) 01/2021 - 10/2009
3	Pulmonary Arterial Hypertension 01/2019 - 10/2012
3	Body Weight (Weight, Body) 09/2015 - 08/2004
3	Reperfusion Injury 07/2014 - 09/2009
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 06/2022 - 03/2020
2	Disease Progression 10/2021 - 01/2021
2	Osteoporosis 01/2021 - 01/2018
2	Muscular Diseases (Myopathy) 07/2020 - 01/2020
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 01/2016
2	Septic Shock (Toxic Shock Syndrome) 01/2019 - 01/2017
2	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2019 - 01/2016
2	Cardiomyopathies (Cardiomyopathy) 01/2018 - 12/2012
2	Hyperlipidemias (Hyperlipidemia) 12/2017 - 09/2006
2	Overweight 09/2015 - 02/2011
2	Peripheral Arterial Occlusive Disease 1 09/2015 - 01/2003
2	Kidney Diseases (Kidney Disease) 08/2014 - 05/2011
2	Albuminuria 10/2012 - 10/2008
2	Alzheimer Disease (Alzheimer's Disease) 01/2012 - 01/2008
2	Pre-Eclampsia (Preeclampsia) 01/2010 - 02/2004
2	Chronic Kidney Failure (Chronic Renal Failure) 12/2009 - 05/2009
2	Proteinuria 10/2008 - 07/2005
2	Erectile Dysfunction 12/2005 - 08/2002
1	COVID-19 10/2021
1	Hypoxia (Hypoxemia) 01/2021

Drug/Important Bio-Agent (IBA)

29	Arginine (L-Arginine)FDA Link 12/2021 - 01/2003
28	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2021 - 02/2004
24	HomoarginineIBA 06/2022 - 09/2013
23	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2006
16	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022 - 08/2002
14	symmetric dimethylarginineIBA 10/2021 - 02/2010
13	Nitric Oxide Synthase (NO Synthase)IBA 01/2021 - 08/2002
13	dimethylarginineIBA 01/2018 - 08/2002
7	LipidsIBA 01/2022 - 12/2014
7	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2022 - 10/2015
7	EnzymesIBA 06/2017 - 12/2009
6	glycine amidinotransferase (arginine-glycine amidinotransferase)IBA 01/2022 - 09/2013
6	Telmisartan (Micardis)FDA Link 10/2008 - 07/2005
5	IsoprostanesIBA 01/2022 - 12/2003
4	Amino Acids FDA Link 06/2022 - 01/2015
4	CreatineIBA 01/2022 - 03/2020
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2020 - 07/2009
4	Angiotensin IIIBA 01/2016 - 05/2009
4	C-Reactive ProteinIBA 02/2011 - 07/2004
4	Nisoldipine FDA Link 10/2007 - 09/2006
3	F2-Isoprostanes (F2 Isoprostanes)IBA 01/2022 - 05/2006
3	Proteins (Proteins, Gene)FDA Link 03/2021 - 09/2015
3	Biological ProductsIBA 10/2020 - 08/2004
3	HDL LipoproteinsIBA 01/2019 - 02/2011
3	Clopidogrel (Plavix)FDA Link 12/2017 - 07/2006
3	HDL CholesterolIBA 01/2016 - 12/2005
3	dimethylargininaseIBA 01/2012 - 12/2009
3	Angiotensin Receptor AntagonistsIBA 10/2008 - 07/2005
3	Antihypertensive Agents (Antihypertensives)IBA 10/2008 - 09/2006
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 10/2007 - 09/2006
3	8-epi-prostaglandin F2alphaIBA 05/2006 - 02/2004
2	Prostaglandin H2 Thromboxane A2 ReceptorsIBA 01/2022 - 01/2022
2	Simvastatin (Zocor)FDA LinkGeneric 07/2020 - 01/2020
2	Ranolazine FDA Link 01/2019 - 01/2016
2	Pharmaceutical PreparationsIBA 03/2018 - 01/2017
2	NitratesIBA 11/2017 - 08/2004
2	Insulin (Novolin)FDA Link 09/2015 - 09/2006
2	Glucose (Dextrose)FDA LinkGeneric 09/2015 - 12/2005
2	Oxidants (Oxidizing Agents)IBA 07/2014 - 07/2006
2	LDL Lipoproteins (beta Lipoproteins)IBA 02/2011 - 07/2004
2	CholesterolIBA 07/2009 - 08/2004
2	Valsartan (Vals)FDA Link 10/2008 - 07/2005
2	CreatinineIBA 10/2008 - 08/2007
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2008 - 07/2006
1	S(8)IBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	omega-Chloroacetophenone (Mace)IBA 04/2021
1	trimethyllysineIBA 04/2021
1	cadherin 5IBA 03/2021
1	Cadherins (E-Cadherin)IBA 03/2021

Therapy/Procedure

4	Therapeutics 10/2012 - 07/2006
2	Patient Readmission 12/2021 - 02/2012
1	Catheter Ablation 01/2022